GSK's £1.9 Billion Cost-Cutting Plan and £400 Million Investment in Cambridge R&D Center: Moving 1,000 Scientists to Accelerate Drug Development

GSK has announced a £1.9 billion cost-cutting program as part of its strategy to accelerate drug development under new CEO Luke Miels. The company plans to invest £400 million in its new Cambridge R&D center, relocating over 1,000 scientists to the site. GSK will close its R&D facility in Stevenage by 2029 and upgrade laboratories in Ware. The firm aims to launch 20 phase 3 trials and redirect resources toward innovative drug development. Shares rose 6% post-announcement, reflecting confidence in the UK's life sciences ecosystem. The move underscores GSK's commitment to leveraging the 'golden triangle' of Cambridge, Oxford, and London, a hub for biomedical research and academic collaboration.

The semiconductor and technology supply chain dynamics suggest this could reshape pharmaceutical R&D investment priorities, particularly in light of global chip shortages and the geopolitical tensions over rare earth elements.